UMIN試験ID | UMIN000042920 |
---|---|
受付番号 | R000048998 |
科学的試験名 | |
一般公開日(本登録希望日) | 2021/01/06 |
最終更新日 | 2021/01/06 00:02:14 |
日本語
英語
Prophylaxis of oral mucositis with iodine solution in head & neck cancer patients during chemoradiation, a randomized controlled trial.
日本語
英語
Prophylaxis of oral mucositis with iodine solution in head & neck cancer patients during chemoradiation, a randomized controlled trial.
日本語
英語
Prophylaxis of oral mucositis with iodine solution in head & neck cancer patients during chemoradiation, a randomized controlled trial.
日本語
英語
Prophylaxis of oral mucositis with iodine solution in head & neck cancer patients during chemoradiation, a randomized controlled trial.
アジア(日本以外)/Asia(except Japan) |
日本語
英語
Head and neck cancer
血液・腫瘍内科学/Hematology and clinical oncology |
悪性腫瘍/Malignancy
いいえ/NO
日本語
英語
To find out the clinical efficacy of iodine solution for prophylaxis of concurrent chemoradiation induced oral mucositis in head and neck cancer patients
有効性/Efficacy
日本語
英語
探索的/Exploratory
実務的/Pragmatic
該当せず/Not applicable
日本語
英語
Oral Mucositis Assessment Scale
日本語
英語
- Pain score
- Impact on swallowing score
- Incidence, severity, onset, & duration of oral mucositis
- Analgesic drug use
- Total treatment break
- Secondary infection of oral mucosa.
介入/Interventional
並行群間比較/Parallel
ランダム化/Randomized
個別/Individual
二重盲検/Double blind -all involved are blinded
プラセボ・シャム対照/Placebo
はい/YES
いいえ/NO
施設を考慮していない/Institution is not considered as adjustment factor.
はい/YES
封筒法/Numbered container method
2
予防・検診・検査/Prevention
医薬品/Medicine |
日本語
英語
- Iodine solution (Intervention)
- Gargle 30 ml for 30 seconds
- 3 times a day after meal
- From the first day of concurrent chemoradiation to the day of completion
日本語
英語
- Normal saline solution (Control)
- Gargle 30 ml for 30 seconds
- 3 times a day after meal
- From the first day of concurrent chemoradiation to the day of completion
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
18 | 歳/years-old | より上/< |
70 | 歳/years-old | 未満/> |
男女両方/Male and Female
日本語
英語
1) Patients should be diagnosed with head and neck cancer without distant metastasis.
2) Patients should be between 18 -70 years old of age.
3) Patient should be receiving concurrent chemotherapy with a platinum-based agent.
4) Oral mucosa should be included in the radiation field.
5) The planned radiation dose to the primary tumor should exceed 50 Gy.
日本語
英語
1) Patients with an Eastern Cooperative Oncology Group Performance Score more than 2.
2) Patients with an allergy to iodine and/or seafood.
3) Patients who were unable to take part in the follow up schedule.
4) Patients who were pregnant or lactating.
5) Patients who had undergone prior radiation therapy.
6) Patients who were diagnosed with more than one primary cancer.
7) Patients who were diagnosed with hematologic malignancies.
8) Patients who were to undergo radiation therapy with altered fractionation.
9) Patients who were previously treated with hyperbaric oxygen therapy.
50
日本語
名 | |
ミドルネーム | |
姓 |
英語
名 | YOTDANAI |
ミドルネーム | |
姓 | NAMUANGCHAN |
日本語
英語
Khon Kaen University
日本語
英語
Division of Radiation Oncology, Department of Radiology, Faculty of Medicine
40002
日本語
英語
123 Mittraphap road, Nai Muang Subdistrict, Muang District, Khon Kaen, THAILAND
+66-83-673-6731
yotdna@kku.ac.th
日本語
名 | |
ミドルネーム | |
姓 |
英語
名 | YOTDANAI |
ミドルネーム | |
姓 | NAMUANGCHAN |
日本語
英語
Khon Kaen University
日本語
英語
Division of Radiation Oncology, Department of Radiology, Faculty of Medicine
40002
日本語
英語
123 Mittraphap road, Nai Muang Subdistrict, Muang District, Khon Kaen, THAILAND
+66-83-673-6731
yotdna@kku.ac.th
日本語
その他
英語
Faculty of Medicine, Khon Kaen University
日本語
日本語
日本語
英語
日本語
その他
英語
Faculty of Medicine, Khon Kaen University
日本語
日本語
その他の国の官庁/Government offices of other countries
日本語
英語
THAI
日本語
英語
日本語
英語
日本語
英語
Center for Ethics in Human Research, Khon Kaen University
日本語
英語
Room 5317, 3rd Floor Wadwichakarn Building, Faculty of Medicine, Khon Kaen University, Mittraphap road, Nai Muang Subdistrict, Muang District, Khon Kaen, 40002, THAILAND
+66-89-714-1913
eckku@kku.ac.th
いいえ/NO
日本語
英語
日本語
英語
Srinagarind Hospital (Khon Kaen, THAILAND)
2021 | 年 | 01 | 月 | 06 | 日 |
https://drive.google.com/open?id=1RuwgCmxwKpKBn__Kcv1UXiUeQHQujZEe&authuser=yotdna%40kku.ac.th&usp=d
未公表/Unpublished
https://drive.google.com/open?id=1WPtRZk34j3kLMQSRVmy30tbOqtqs6Epy&authuser=yotdna%40kku.ac.th&usp=d
20
日本語
英語
As in attached URL above
2021 | 年 | 01 | 月 | 05 | 日 |
日本語
英語
日本語
英語
Participants in this study consisted of twelve men and eight women, with mean ages of 53.90 & 56.30 years in the treatment & control groups respectively. Primary cancer sites were; oral cavity (30%), oropharynx (30%), nasopharynx (30%) and nasal cavity (10%). Most of the patients had locally advanced disease; Stage III (35%) and Stage IV (50%). These were assigned to definitive treatment (80%), while the rest were post-operative (20%). Radiation techniques were 3D-CRT (50%) and IMRT/VMAT (50%). The most common concurrent chemotherapy regimen was weekly cisplatin (55%). The median radiation dose was 70 Gy in both groups. The mean oral cavity doses were 59.30 & 49.72 Gy, the mean radiation volumes were 1269.99 & 1404.59 cm3 and the mean durations of treatment were 64.40 & 57.80 days, in the treatment & control groups respectively. Note that the mean oral cavity dose was about 10 Gy higher in the iodine solution group. There is no statistically significant difference in characteristic data between the two groups.
日本語
英語
After obtaining informed consent, the patients were randomly assigned to the treatment or control group, by stratified simple random sampling with primary cancer site (Oral cavity vs Oropharynx vs Nasopharynx vs Nasal cavity), and stage groups (I vs II vs III vs IV). Opaque envelopes containing a card marked with the letter A or B were then picked by the patients, assigning themselves to either the treatment or control group.
日本語
英語
The reported mouthwashes' adverse effects were nausea & unfavorable taste/odor.
日本語
英語
An oral examination was done before the start of CCRT, at weekly intervals during CCRT, at the end of CCRT, and 4 weeks after completion of CCRT, using the Oral Mucositis Assessment Scale (OMAS) and World Health Organization (WHO) criteria for grading of oral mucositis.
日本語
英語
日本語
英語
試験終了/Completed
2019 | 年 | 01 | 月 | 10 | 日 |
2019 | 年 | 01 | 月 | 28 | 日 |
2019 | 年 | 03 | 月 | 20 | 日 |
2019 | 年 | 12 | 月 | 25 | 日 |
2020 | 年 | 01 | 月 | 25 | 日 |
2020 | 年 | 02 | 月 | 20 | 日 |
2020 | 年 | 03 | 月 | 18 | 日 |
日本語
英語
2021 | 年 | 01 | 月 | 06 | 日 |
2021 | 年 | 01 | 月 | 06 | 日 |
日本語
https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000048998
英語
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048998
研究計画書 | |
---|---|
登録日時 | ファイル名 |
研究症例データ仕様書 | |
---|---|
登録日時 | ファイル名 |
研究症例データ | |
---|---|
登録日時 | ファイル名 |